Skip Navigation


JAC Advance Access originally published online on November 18, 2002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
50/6/771    most recent
dkg005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by García-Lerma, J. G.
Right arrow Articles by Heneine, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by García-Lerma, J. G.
Right arrow Articles by Heneine, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2002) 50, 771-774
© 2002 The British Society for Antimicrobial Chemotherapy

Leading articles

Rapid biochemical assays for phenotypic drug resistance testing of HIV-1

J. Gerardo García-Lerma* and Walid Heneine

HIV and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, MS G-19, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA

Keywords: HIV, drug resistance

The first 150 words of the full text of this article appear below.


   Background
 
Treatment of HIV-1-infected persons with antiretroviral drugs has significantly reduced the rate of HIV and AIDS-related morbidity and mortality. To date, the US Food and Drug Administration (FDA) has approved 19 antiretroviral drugs for treatment of HIV-1 infections, including 16 unique inhibitors of either HIV-1 reverse transcriptase (RT) or protease. Selecting a combination regimen that maximally suppresses virus replication is critical for treatment success, since failure to achieve viral suppression may result in the emergence of viruses carrying drug resistance mutations. Drug-resistant viruses may be selected from pre-existing viral quasispecies or may be generated de novo. The generation of drug-resistant variants is a consequence of the high mutation rates and replication of HIV-1. If an HIV-1-infected person produces an estimated 1010 virions daily and each genome contains an average of one mutation, every possible single mutation associated with drug resistance may be generated daily.1,2 Estimates based on the rate . . . [Full Text of this Article]


   Resistance testing
 

   Rapid assays for phenotypic drug resistance testing
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?